Humane Genomics

New York, NY, USA

7 employees

Biotech/Pharma

Seed · $8.1M

About Humane Genomics

Humane Genomics is a synthetic biology platform developing engineered oncolytic (cancer-killing) viruses as precision cancer therapeutics. The company uses synthesized DNA and a proprietary digital design system to construct RNA viruses that selectively infect and replicate within cancer cells while sparing healthy tissue. Its initial clinical focus is liver cancer, with additional programs targeting bone, lung, and brain cancers.

Company details

Team Size7

LocationNew York, NY, USA

IndustryBiotech/Pharma

Funding

Total raised

$8.1M

Last stage

Seed

Investors

Union Square Ventures

Y Combinator

2048 Ventures

MMana Ventures

HHumba Ventures

Founders

Chad Moles

M.A. in Biotechnology from Columbia University with a thesis on synthetic genome engineering. Leads all scientific and research operations at Humane Genomics.

Peter Weijmarshausen

Serial entrepreneur and former founder & CEO of Shapeways. BSc Applied Physics. Co-founded Humane Genomics to engineer synthetic viruses as cancer therapies.

Andrew Hessel

MSc Microbial Genetics. Co-executive Director of the Genome Project-write and past co-chair of Biotech and Bioinformatics at Singularity University.

What happens next.

No applications, no recruiter spam. Just the intro.

Confirm the fit

A few questions to make sure this role is the right shape for you. Two minutes.

I pitch you to the company

I write the intro, send it to the founder, and handle the back-and-forth.

A meeting lands on your calendar

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.